Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Semarion
United Kingdom
- Cambridge, Cambridgeshire
- 02/04/2026
- Unknown
- $3,800,000
Unlock more data from adherent cell assays.
Our SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models within a single well and dramatically increase experimental throughput.
SemaCyte® microcarriers are ultra-miniaturised, barcoded micro-wells that carry small colonies of adherent cells while preserving their natural morphology. These microcarriers can be moved with standard liquid handling tools, cryopreserved in biobanks, pooled for multiplexed experiments, and decoded using optical barcodes.
By transforming adherent cells into mobile, automation-ready reagents, SemaCytes enable researchers to:
• Multiplex different cell models within a single well
• Generate assay-ready adherent cells that can be thawed and used on demand
• Reduce assay preparation time and increase throughput by up to 10×
• Integrate seamlessly with standard microplate workflows, automation, and imaging systems
Semarion is a University of Cambridge spin-out from the Cavendish Laboratory, combining materials science, microfabrication, and cell biology to remove bottlenecks in adherent cell screening.
We collaborate with leading pharmaceutical companies and technology partners to bring scalable multiplexed cell assays to laboratories worldwide.
- Industry Biotechnology Research
- Website https://www.semarion.com/
- LinkedIn https://www.linkedin.com/company/semarion/
Related People
Jeroen VerheyenCo Founder
United Kingdom -
Greater Cambridge Area
Jeroen Verheyen works at the interface of emerging technologies and life sciences. As Co-Founder & CEO at Semarion he has led the development and commercialization of a next-gen live-cell screen platform for drug discovery. By adopting technologies from the microchip, nanomagentism, and smart materials space, Semarion developed a highly versatile microcarrier platform that turns adherent cells into liquid reagents.
He holds a degree in Biomedical Sciences (MSc, Magna Cum Laude) & Nanotechnology (MSc/MEng, Magna Cum Laude), studied Clinical Neuroscience (PhD, no submitted), and has done research on point-of-care (PoC) diagnostics, stem cell therapy, RNAi therapy, drug delivery systems for cancer, nanomaterials, biosensors, microfluidics, photocatalysis, immunology, disease models, dentistry, etc.
His work with startups (e.g. Cambridge Solar Environmental Solutions), social enterprises (e.g. Majicom), educational organizations (e.g. Cambridge Technology & Enterprise Club), consulting firms (e.g. Cambridge Innovation Consulting), SMEs (e.g. Smartbleach International), and government (e.g. H1N1 flu crisis team) has yielded insight in business development, healthcare policy, product development, fundraising and investment, entrepreneurship, team management, intellectual property, regulatory approval, commercialization strategy, marketing, project management, licensing, technology assessment, etc.
Jeroen is an advocate for optimism, openness, creative thinking, sustainable abundance, human capabilities, and kindness.
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Variance | $21,500,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
TippingPoint Biosciences | $4,500,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)